eligibility_summary
Eligibility: Epithelial ovarian/fallopian tube/primary peritoneal cancer with high FRα by VENTANA (≥75% cells ≥2+). BRCA-mut must have had PARPi. Washouts: systemic ≥5 half-lives/4 wks, focal RT ≥2 wks. Toxicities ≤Grade1 (except alopecia). WOCBP: effective contraception and negative test ≤4 days pre-dose. Exclude: borderline/non-epithelial, primary platinum-refractory (≤3 mo), >Grade1 neuropathy, significant ocular disease, steroid/vasoconstrictor eyedrops, prior MIRV/FRα agents.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
A randomized phase 2 trial in recurrent FR-alpha–high ovarian cancer tests strategies to prevent ocular AEs during mirvetuximab soravtansine (MIRV). Interventions: MIRV (IMGN853), an antibody-drug conjugate with an anti–FR-alpha mAb (M9346A) linked via a cleavable disulfide to DM4, a maytansinoid microtubule inhibitor, prednisolone acetate 1% eye drops (topical corticosteroid) to suppress ocular surface inflammation via glucocorticoid receptor signaling, brimonidine tartrate eye drops (topical alpha-2 adrenergic agonist) to vasoconstrict conjunctival vessels and limit exposure, and lubricating eye drops (artificial tears) to dilute/protect the cornea. Targets: FR-alpha–positive epithelial ovarian cancer cells, intracellular microtubules, ocular inflammatory pathways, alpha-2 adrenergic receptors regulating ocular vascular tone.